Wednesday, July 8, 2026

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

Bright Minds Biosciences is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker DRUG. Primary therapeutic focus areas include Cocaine-Related Disorders, Cocaine Dependence, Nicotine Depen

19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Clinical program

naltrexone for extended release injectable suspension

Approved · small molecule · Substance-Related Disorders

naltrexone for extended release injectable suspension for Substance-Related Disorders is a Approved program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

← All BRIGHT MINDS BIOSCIENCES INC. projects Approved small molecule completed

Internal code RIH VIVITROL -01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
BRIGHT MINDS BIOSCIENCES INC.
Phase
Approved
Modality
small_molecule
Indication
Substance-Related Disorders
Status
completed
Trials
1